Merel van Diepen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Merel van Diepen has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Friedo Wilhelm Dekker
Department of Clinical Epidemiology, Leiden University Medical Center , Leiden
11 shared publications - Joris I. Rotmans
Department of Internal Medicine Leiden University Medical Center (LUMC) Leiden The Netherlands
6 shared publications - Roemer J. Janse
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
6 shared publications - Chava L. Ramspek
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
4 shared publications - Kitty J. Jager
ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam , Amsterdam
4 shared publications - Carmine Zoccali
Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy
3 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
Large language models: what are they and how can the clinician use them?
Background: Large Language Models (LLMs) such as ChatGPT represent the latest advancements in natural language processing and artificial intelligence. These models are increasingly being explored for applications in medicine and healthcare, including nephrology. Objectives: To provide an accessible introduction to LLMs, explain their underlying concepts, discuss their challenges and limitations in medical applications, highlight opportunities for their use in medicine and nephrology, and offer perspectives for future research. Methods: This article synthesizes recent literature on LLMs in medicine with examples in nephrology. It also reviews key concepts such as word embeddings, the Transformer architecture, and the pretrain-then-finetune paradigm. Moreover, the article discusses the differences between standard pretrained language models and LLMs Results: LLMs have demonstrated potential in various clinical tasks, including patient triaging, phenotyping, and report generation. In nephrology, LLMs have been used for triaging patient communications, answering exam questions, and informing patients about chronic kidney disease and transplantation. However, challenges remain, such as privacy, the generation of false information (hallucinations), data and model bias, reproducibility and language coverage. Opportunities include making health information more accessible for patients, reducing administrative burdens for healthcare workers, and tackling complex clinical tasks with multi-agent systems. Conclusions: LLMs offer transformative potential in medicine, but their deployment must address issues of hallucination, bias, privacy, the environment, and more. Integrating complementary technologies and rigorous evaluation is essential for safe and effective use. Collaboration among AI researchers, clinicians, and policymakers is crucial to maximize benefits and minimize risks, ensuring transparency, accountability, and inclusivity in LLM development.
- 5 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
Open AccessLarge language models: what are they and how can the clinician use them?
Background: Large Language Models (LLMs) such as ChatGPT represent the latest advancements in natural language processing and artificial intelligence. These models are increasingly being explored for applications in medicine and healthcare, including nephrology. Objectives: To provide an accessible introduction to LLMs, explain their underlying concepts, discuss their challenges and limitations in medical applications, highlight opportunities for their use in medicine and nephrology, and offer perspectives for future research. Methods: This article synthesizes recent literature on LLMs in medicine with examples in nephrology. It also reviews key concepts such as word embeddings, the Transformer architecture, and the pretrain-then-finetune paradigm. Moreover, the article discusses the differences between standard pretrained language models and LLMs Results: LLMs have demonstrated potential in various clinical tasks, including patient triaging, phenotyping, and report generation. In nephrology, LLMs have been used for triaging patient communications, answering exam questions, and informing patients about chronic kidney disease and transplantation. However, challenges remain, such as privacy, the generation of false information (hallucinations), data and model bias, reproducibility and language coverage. Opportunities include making health information more accessible for patients, reducing administrative burdens for healthcare workers, and tackling complex clinical tasks with multi-agent systems. Conclusions: LLMs offer transformative potential in medicine, but their deployment must address issues of hallucination, bias, privacy, the environment, and more. Integrating complementary technologies and rigorous evaluation is essential for safe and effective use. Collaboration among AI researchers, clinicians, and policymakers is crucial to maximize benefits and minimize risks, ensuring transparency, accountability, and inclusivity in LLM development.
- Open Access
- 18 September 2026
- Published by Elsevier in SSRN Electronic Journal
Improved prediction of BK viremia after kidney transplantation using BK serology of donor and recipient – a cohort study
Kidney transplant (KTx) care urgently needs a reliable marker to anticipate BK polyomavirus (BKPyV) infection. BKPyV viremia may lead to BK virus-associated nephropathy (BKVAN) or even graft failure. As pre-KTx BKPyV seroresponse is thought reflect renal BKPyV load, we assess and validate the added prognostic value of BKPyV serology in predicting BKPyV viremia. A cohort of 347 living-donor KTx recipients with 69 BKPyV viremia events was used to develop a Cox proportional hazards model with expert-chosen predictors: induction (alemtuzumab/basiliximab), #HLA-ABDR mismatch, dialysis vintage, and related or unrelated donor. A second model additionally contained pre-KTx BKPyV IgG seroresponse of donor and recipient. Performance of both models was compared. The expert model performed poorly to predict BKPyV viremia. After BKPyV serology was added, overall performance remained limited, but improved compared to the expert model. C-statistic increased (0.57 [0.50–0.63] to 0.63 [0.65-0.70]), goodness-of-fit improved (p=0.035), Brier score improved, and the new model assigned 68% of cases a higher 1-year risk. Similar improvement was seen the temporal validation cohort (n=407, n=111 events). Pre-KTx BKPyV serology of donor and recipient improves the prediction BKPyV viremia. Implementing BKPyV serology measurement in routine care may help to personalize BKPyV screening frequency or timely change dosing of immunosuppression.
- 18 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImproved prediction of BK viremia after kidney transplantation using BK serology of donor and recipient – a cohort study
Kidney transplant (KTx) care urgently needs a reliable marker to anticipate BK polyomavirus (BKPyV) infection. BKPyV viremia may lead to BK virus-associated nephropathy (BKVAN) or even graft failure. As pre-KTx BKPyV seroresponse is thought reflect renal BKPyV load, we assess and validate the added prognostic value of BKPyV serology in predicting BKPyV viremia. A cohort of 347 living-donor KTx recipients with 69 BKPyV viremia events was used to develop a Cox proportional hazards model with expert-chosen predictors: induction (alemtuzumab/basiliximab), #HLA-ABDR mismatch, dialysis vintage, and related or unrelated donor. A second model additionally contained pre-KTx BKPyV IgG seroresponse of donor and recipient. Performance of both models was compared. The expert model performed poorly to predict BKPyV viremia. After BKPyV serology was added, overall performance remained limited, but improved compared to the expert model. C-statistic increased (0.57 [0.50–0.63] to 0.63 [0.65-0.70]), goodness-of-fit improved (p=0.035), Brier score improved, and the new model assigned 68% of cases a higher 1-year risk. Similar improvement was seen the temporal validation cohort (n=407, n=111 events). Pre-KTx BKPyV serology of donor and recipient improves the prediction BKPyV viremia. Implementing BKPyV serology measurement in routine care may help to personalize BKPyV screening frequency or timely change dosing of immunosuppression.
- Open Access
- 27 March 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (9) , 2066-2074
Vascular Access Surgery Timing
Key Points: Only 32% of elderly patients with ESKD in Europe started hemodialysis with a functional fistula that was created on time. Vascular access was created early in 42% and late in 26% of patients, exposing these patients to unused fistulas or catheter dependency. Eventually, 90% of all patients after fistula creation started hemodialysis within the mean follow-up period of 30 months. Background: Timing vascular access creation for older patients with ESKD is challenging. Autologous arteriovenous fistulas (AVF) are often created too early, leading to unused fistulas, or too late, necessitating central venous catheters (CVC). This study reports on vascular access creation in relation to hemodialysis initiation in European practice. Methods: This study is a secondary analysis of the European Quality cohort: a prospective observational study that recruited patients aged ≥65 years with stage 4 or 5 CKD from six European countries. Patients were selected once their eGFR dropped below 15 ml/min per 1.73 m 2 , if they received a vascular access, and had at least 6 months of follow-up. Vascular access timing was categorized into three groups: early (no dialysis within 6 months after AVF creation), on time (dialysis initiated with an AVF within 6 months), and late (hemodialysis initiated with a CVC before or within 6 months after AVF creation). Results: A total of 332 patients from the European Quality cohort were analyzed: 221 patients (67%) received an AVF as first vascular access and 111 patients (33%) a CVC. Among the latter, 53 patients (48%) underwent subsequent AVF creation, whereas for the remaining 58 patients, CVC was considered the intended vascular access strategy. At dialysis initiation, 158 patients (54%) used an AVF, while 136 patients (46%) used a CVC. AVF creation was on time in 88 of 274 patients (32%), early in 114 patients (42%), and late in 72 patients (26%). Despite high rates of early AVF creation, most fistulas were eventually used, as 90% of patients initiated hemodialysis within 3 years. Conclusions: Only 32% of elderly patients with ESKD started hemodialysis with a functional AVF created on time (within the 6-month window), while 42% had early and 26% late creation. Clinical prediction tools are needed to optimize vascular access timing.
- 27 March 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (9) , 2066-2074
Open AccessVascular Access Surgery Timing
Key Points: Only 32% of elderly patients with ESKD in Europe started hemodialysis with a functional fistula that was created on time. Vascular access was created early in 42% and late in 26% of patients, exposing these patients to unused fistulas or catheter dependency. Eventually, 90% of all patients after fistula creation started hemodialysis within the mean follow-up period of 30 months. Background: Timing vascular access creation for older patients with ESKD is challenging. Autologous arteriovenous fistulas (AVF) are often created too early, leading to unused fistulas, or too late, necessitating central venous catheters (CVC). This study reports on vascular access creation in relation to hemodialysis initiation in European practice. Methods: This study is a secondary analysis of the European Quality cohort: a prospective observational study that recruited patients aged ≥65 years with stage 4 or 5 CKD from six European countries. Patients were selected once their eGFR dropped below 15 ml/min per 1.73 m 2 , if they received a vascular access, and had at least 6 months of follow-up. Vascular access timing was categorized into three groups: early (no dialysis within 6 months after AVF creation), on time (dialysis initiated with an AVF within 6 months), and late (hemodialysis initiated with a CVC before or within 6 months after AVF creation). Results: A total of 332 patients from the European Quality cohort were analyzed: 221 patients (67%) received an AVF as first vascular access and 111 patients (33%) a CVC. Among the latter, 53 patients (48%) underwent subsequent AVF creation, whereas for the remaining 58 patients, CVC was considered the intended vascular access strategy. At dialysis initiation, 158 patients (54%) used an AVF, while 136 patients (46%) used a CVC. AVF creation was on time in 88 of 274 patients (32%), early in 114 patients (42%), and late in 72 patients (26%). Despite high rates of early AVF creation, most fistulas were eventually used, as 90% of patients initiated hemodialysis within 3 years. Conclusions: Only 32% of elderly patients with ESKD started hemodialysis with a functional AVF created on time (within the 6-month window), while 42% had early and 26% late creation. Clinical prediction tools are needed to optimize vascular access timing.
- Open Access
- 18 March 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 194, 112232
Concordance analysis of the short-form of the PROBAST as a screening tool: two-step risk of bias assessment showing only underestimation of risk of bias
- 18 March 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 194, 112232
Open AccessConcordance analysis of the short-form of the PROBAST as a screening tool: two-step risk of bias assessment showing only underestimation of risk of bias
- Open Access
Prevalence, incidence and risk factors of chronic kidney disease in people with diabetes and hypertension, and the prognosis and kidney function decline in Indonesia: a multicentre cross-sectional study in primary care centres
Objectives: To examine chronic kidney disease (CKD) prevalence, incidence, prognosis, kidney function decline and associated risk factors among people with diabetes and/or hypertension. Design: Cross-sectional multicentre study. Setting: 14 primary care centres across Jakarta. Participants: Adults (≥18 years) with diabetes and/or hypertension were included. Exclusion criteria were receiving kidney replacement therapy, language barrier, cognitive impairments, refusal to consent and pregnancy. Participants were grouped into three categories: hypertension only, diabetes only and both. Interventions: None. Primary and secondary outcomes: Primary outcomes included CKD prevalence, incidence, number-needed-to-screen, KDIGO-based prognosis and annual kidney function decline. Secondary outcomes were risk factors for CKD, uncontrolled blood glucose, blood pressure and albuminuria. Results: A total of 1263 participants were enrolled: 51% had hypertension, 17.6% diabetes and 31.4% both. Mean age: 57.1±10.2 years, 72.2% female and 76% obese. Renin angiotensin aldosterone system inhibitors were prescribed in 32.3%, and only 1.2% used insulin despite a median glycated haemoglobin of 7.5% (IQR: 6.5–9.1). CKD prevalence was 14.8%, with an incidence rate of 9.1 per 100 person-years; number-needed-to-screen was 7. Based on KDIGO criteria, 48.9% were at moderate-to-very high risk of adverse outcomes. Baseline estimated glomerular filtration rate was 80.9 (SE=10.1), declining by 4.7 (SE=9.9) mL/min/1.73 m 2 annually. CKD incidence was higher with albuminuria (OR 3.6, p=0.007) in the combined group; older age (OR 4.5, p<0.001), male (OR 2.3, p=0.026) and haematuria (OR 2.5, p=0.034) in the hypertension group and cardiovascular disease (OR 14.9, p=0.004) in the diabetes group. Conclusions: CKD burden is high among people with diabetes and hypertension. Nearly half were at elevated risk despite preserved kidney function, highlighting the need for targeted early screening.
Open AccessPrevalence, incidence and risk factors of chronic kidney disease in people with diabetes and hypertension, and the prognosis and kidney function decline in Indonesia: a multicentre cross-sectional study in primary care centres
Objectives: To examine chronic kidney disease (CKD) prevalence, incidence, prognosis, kidney function decline and associated risk factors among people with diabetes and/or hypertension. Design: Cross-sectional multicentre study. Setting: 14 primary care centres across Jakarta. Participants: Adults (≥18 years) with diabetes and/or hypertension were included. Exclusion criteria were receiving kidney replacement therapy, language barrier, cognitive impairments, refusal to consent and pregnancy. Participants were grouped into three categories: hypertension only, diabetes only and both. Interventions: None. Primary and secondary outcomes: Primary outcomes included CKD prevalence, incidence, number-needed-to-screen, KDIGO-based prognosis and annual kidney function decline. Secondary outcomes were risk factors for CKD, uncontrolled blood glucose, blood pressure and albuminuria. Results: A total of 1263 participants were enrolled: 51% had hypertension, 17.6% diabetes and 31.4% both. Mean age: 57.1±10.2 years, 72.2% female and 76% obese. Renin angiotensin aldosterone system inhibitors were prescribed in 32.3%, and only 1.2% used insulin despite a median glycated haemoglobin of 7.5% (IQR: 6.5–9.1). CKD prevalence was 14.8%, with an incidence rate of 9.1 per 100 person-years; number-needed-to-screen was 7. Based on KDIGO criteria, 48.9% were at moderate-to-very high risk of adverse outcomes. Baseline estimated glomerular filtration rate was 80.9 (SE=10.1), declining by 4.7 (SE=9.9) mL/min/1.73 m 2 annually. CKD incidence was higher with albuminuria (OR 3.6, p=0.007) in the combined group; older age (OR 4.5, p<0.001), male (OR 2.3, p=0.026) and haematuria (OR 2.5, p=0.034) in the hypertension group and cardiovascular disease (OR 14.9, p=0.004) in the diabetes group. Conclusions: CKD burden is high among people with diabetes and hypertension. Nearly half were at elevated risk despite preserved kidney function, highlighting the need for targeted early screening.
- Open Access
- 20 February 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (4) , sfaf059
When the whole is greater than the sum of its parts: why machine learning and conventional statistics are complementary for predicting future health outcomes
An artificial intelligence boom is currently ongoing, mainly due to large language models, leading to significant interest in artificial intelligence and subsequently also in machine learning (ML). One area where ML is often applied, prediction modelling, has also long been a focus of conventional statistics. As a result, multiple studies have aimed to prove superiority of one of the two scientific disciplines over the other. However, we argue that ML and conventional statistics should not be competing fields. Instead, both fields are intertwined and complementary to each other. To illustrate this, we discuss some essentials of prediction modelling, elaborate on prediction modelling using techniques from conventional statistics, and explain prediction modelling using common ML techniques such as support vector machines, random forests, and artificial neural networks. We then showcase that conventional statistics and ML are in fact similar in many aspects, including underlying statistical concepts and methods used in model development and validation. Finally, we argue that conventional statistics and ML can and should be seen as a single integrated field. This integration can further improve prediction modelling for both disciplines (e.g. regarding fairness and reporting standards) and will support the ultimate goal: developing the best performing prediction models for the patient and healthcare provider.
- 20 February 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (4) , sfaf059
Open AccessWhen the whole is greater than the sum of its parts: why machine learning and conventional statistics are complementary for predicting future health outcomes
An artificial intelligence boom is currently ongoing, mainly due to large language models, leading to significant interest in artificial intelligence and subsequently also in machine learning (ML). One area where ML is often applied, prediction modelling, has also long been a focus of conventional statistics. As a result, multiple studies have aimed to prove superiority of one of the two scientific disciplines over the other. However, we argue that ML and conventional statistics should not be competing fields. Instead, both fields are intertwined and complementary to each other. To illustrate this, we discuss some essentials of prediction modelling, elaborate on prediction modelling using techniques from conventional statistics, and explain prediction modelling using common ML techniques such as support vector machines, random forests, and artificial neural networks. We then showcase that conventional statistics and ML are in fact similar in many aspects, including underlying statistical concepts and methods used in model development and validation. Finally, we argue that conventional statistics and ML can and should be seen as a single integrated field. This integration can further improve prediction modelling for both disciplines (e.g. regarding fairness and reporting standards) and will support the ultimate goal: developing the best performing prediction models for the patient and healthcare provider.
- Open Access
- 19 July 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (8) , sfae225
Dealing with an uncertain future: a survey study on what patients with chronic kidney disease actually want to know
Background: Prognostic uncertainty is a recurring theme among patients with chronic kidney disease (CKD). We developed a survey to explore whether CKD patients want to know more about their future, and if so, which topics they prioritize. In addition, we explored differences between several subgroups. Methods: A survey was constructed and tested in collaboration with the Dutch Kidney Patients Association. The survey consisted of three parts: (i) demographics, (ii) considerations about the future, and (iii) prognostic information. The survey was distributed among CKD patients (all stages) through patient associations and via healthcare professionals in two Dutch hospitals. Descriptive statistics were used to summarize the results. All results were stratified by population, sex, and age. Results: A total of 163 patients (45 CKD, 26 dialysis, and 92 kidney transplantation) participated in the survey. The mean age was 63.9 (SD 12.0) and 48.5% was male. Most patients think about their future with CKD occasionally (56.4%) or often (35.0%). Nearly half of the patients (49.7%) discuss the future with their nephrologist, some (19.6%) do not but would like to, and 20 (15.3%) prefer not to. Most patients (73.6%) want more prognostic information, regardless of it being positive or negative. Key topics to receive prognostic information about were laboratory values, symptoms, and physical well-being. Dialysis patients prioritized mental over physical well-being. CKD patients without kidney replacement therapy (KRT) indicated thinking about, and discussing their future more regularly than KRT patients. Conclusions: Patients with CKD contemplate their future regularly and express interest in receiving prognostic information on a variety of topics. One in five patients currently do not discuss their future with CKD with their nephrologist, despite wanting to do so. These findings underline the need to tailor prognostic information provision to patients’ preferences, advocating more attention to this subject both in research and clinical practice.
- 19 July 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (8) , sfae225
Open AccessDealing with an uncertain future: a survey study on what patients with chronic kidney disease actually want to know
Background: Prognostic uncertainty is a recurring theme among patients with chronic kidney disease (CKD). We developed a survey to explore whether CKD patients want to know more about their future, and if so, which topics they prioritize. In addition, we explored differences between several subgroups. Methods: A survey was constructed and tested in collaboration with the Dutch Kidney Patients Association. The survey consisted of three parts: (i) demographics, (ii) considerations about the future, and (iii) prognostic information. The survey was distributed among CKD patients (all stages) through patient associations and via healthcare professionals in two Dutch hospitals. Descriptive statistics were used to summarize the results. All results were stratified by population, sex, and age. Results: A total of 163 patients (45 CKD, 26 dialysis, and 92 kidney transplantation) participated in the survey. The mean age was 63.9 (SD 12.0) and 48.5% was male. Most patients think about their future with CKD occasionally (56.4%) or often (35.0%). Nearly half of the patients (49.7%) discuss the future with their nephrologist, some (19.6%) do not but would like to, and 20 (15.3%) prefer not to. Most patients (73.6%) want more prognostic information, regardless of it being positive or negative. Key topics to receive prognostic information about were laboratory values, symptoms, and physical well-being. Dialysis patients prioritized mental over physical well-being. CKD patients without kidney replacement therapy (KRT) indicated thinking about, and discussing their future more regularly than KRT patients. Conclusions: Patients with CKD contemplate their future regularly and express interest in receiving prognostic information on a variety of topics. One in five patients currently do not discuss their future with CKD with their nephrologist, despite wanting to do so. These findings underline the need to tailor prognostic information provision to patients’ preferences, advocating more attention to this subject both in research and clinical practice.
- Open Access
- 17 July 2024
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 40 (1) , 27-33
When impact trials are not feasible: alternatives to study the impact of prediction models on clinical practice
Patients with kidney disease have an uncertain future, with prognosis varying greatly per patient. To get a better idea of what the future holds and tailor interventions to the individual patient, prediction models can be of great value. Before a prediction model can be applied in practice, its performance should be measured in target populations of interest (i.e. external validation) and whether or not it helps improve clinical practice (i.e. whether it impacts clinical practice) should be determined. The impact would ideally be determined using an impact trial, but such a trial is often not feasible, and the impact of prediction models is therefore rarely assessed. As a result, prediction models that may not be so impactful may end up in clinical practice and impactful models may not be implemented due to a lack of impact studies. Ultimately, many prediction models end up never being implemented, resulting in much research waste. To allow researchers to get an indication of a prediction model's impact on clinical practice, alternative methods to assess a prediction model's impact are important. In this paper, we discuss several alternatives, including interviews, case-based surveys, decision comparisons, outcome modelling, before–after analyses and decision curve analyses. We discuss the general idea behind these approaches, including what information can be gathered from such studies and important pitfalls. Lastly, we provide examples of the different alternatives.
- 17 July 2024
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 40 (1) , 27-33
Open AccessWhen impact trials are not feasible: alternatives to study the impact of prediction models on clinical practice
Patients with kidney disease have an uncertain future, with prognosis varying greatly per patient. To get a better idea of what the future holds and tailor interventions to the individual patient, prediction models can be of great value. Before a prediction model can be applied in practice, its performance should be measured in target populations of interest (i.e. external validation) and whether or not it helps improve clinical practice (i.e. whether it impacts clinical practice) should be determined. The impact would ideally be determined using an impact trial, but such a trial is often not feasible, and the impact of prediction models is therefore rarely assessed. As a result, prediction models that may not be so impactful may end up in clinical practice and impactful models may not be implemented due to a lack of impact studies. Ultimately, many prediction models end up never being implemented, resulting in much research waste. To allow researchers to get an indication of a prediction model's impact on clinical practice, alternative methods to assess a prediction model's impact are important. In this paper, we discuss several alternatives, including interviews, case-based surveys, decision comparisons, outcome modelling, before–after analyses and decision curve analyses. We discuss the general idea behind these approaches, including what information can be gathered from such studies and important pitfalls. Lastly, we provide examples of the different alternatives.
- Open Access
- 8 April 2024
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 14 (3) , 740-764
The Etiology of Advanced Chronic Kidney Disease in Southeast Asia: A Meta-analysis
Introduction: Chronic kidney disease (CKD) etiology varies greatly between developed and developing countries. In addition, differences in underlying pathogenesis and therapeutic options affect the progression towards advanced-CKD. This meta-analysis aims to identify the etiology of advanced-CKD in Southeast Asia. Methods: A systematic search in four electronic-databases and complementary search on national kidney registries and repository libraries was conducted until July 20, 2023. The risk of bias was assessed using Newcastle–Ottawa Scale for observational studies and Version-2 of Cochrane for intervention studies. A random-effects model was used to estimate pooled prevalence. The protocol is registered in the International Prospective Register of Systematic Reviews PROSPERO; Registration ID:CRD42022300786. Results: We analyzed 81 studies involving 32,834 subjects. The pooled prevalence of advanced-CKD etiologies are diabetic kidney disease (DKD) 29.2% (95%CI 23.88–34.78), glomerulonephritis 20.0% (95%CI 16.84–23.38), hypertension 16.8% (95%CI 14.05–19.70), other 8.6% (95%CI 6.97–10.47), unknown 7.5% (95%CI 4.32–11.50), and polycystic kidney disease 0.7% (95%CI 0.40–1.16). We found a significant increase in DKD prevalence from 21% (9.2%, 95%CI 0.00–33.01) to 30% (95%CI 24.59–35.97) before and after the year 2000. Among upper-middle-income and high-income countries, DKD is the most prevalent (26.8%, 95%CI 21.42–32.60 and 38.9%, 95%CI 29.33–48.79, respectively), while glomerulonephritis is common in lower-middle-income countries (33.8%, 95%CI 15.62–54.81). Conclusion: The leading cause of advanced-CKD in Southeast Asia is DKD, with a substantial proportion of glomerulonephritis. An efficient screening program targeting high-risk populations (diabetes mellitus and glomerulonephritis) is needed, with the aim to delay CKD progression.
- 8 April 2024
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 14 (3) , 740-764
Open AccessThe Etiology of Advanced Chronic Kidney Disease in Southeast Asia: A Meta-analysis
Introduction: Chronic kidney disease (CKD) etiology varies greatly between developed and developing countries. In addition, differences in underlying pathogenesis and therapeutic options affect the progression towards advanced-CKD. This meta-analysis aims to identify the etiology of advanced-CKD in Southeast Asia. Methods: A systematic search in four electronic-databases and complementary search on national kidney registries and repository libraries was conducted until July 20, 2023. The risk of bias was assessed using Newcastle–Ottawa Scale for observational studies and Version-2 of Cochrane for intervention studies. A random-effects model was used to estimate pooled prevalence. The protocol is registered in the International Prospective Register of Systematic Reviews PROSPERO; Registration ID:CRD42022300786. Results: We analyzed 81 studies involving 32,834 subjects. The pooled prevalence of advanced-CKD etiologies are diabetic kidney disease (DKD) 29.2% (95%CI 23.88–34.78), glomerulonephritis 20.0% (95%CI 16.84–23.38), hypertension 16.8% (95%CI 14.05–19.70), other 8.6% (95%CI 6.97–10.47), unknown 7.5% (95%CI 4.32–11.50), and polycystic kidney disease 0.7% (95%CI 0.40–1.16). We found a significant increase in DKD prevalence from 21% (9.2%, 95%CI 0.00–33.01) to 30% (95%CI 24.59–35.97) before and after the year 2000. Among upper-middle-income and high-income countries, DKD is the most prevalent (26.8%, 95%CI 21.42–32.60 and 38.9%, 95%CI 29.33–48.79, respectively), while glomerulonephritis is common in lower-middle-income countries (33.8%, 95%CI 15.62–54.81). Conclusion: The leading cause of advanced-CKD in Southeast Asia is DKD, with a substantial proportion of glomerulonephritis. An efficient screening program targeting high-risk populations (diabetes mellitus and glomerulonephritis) is needed, with the aim to delay CKD progression.
- Open Access
- 14 March 2024
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 39 (12) , 2079-2087
Clinical impact of the Kidney Failure Risk Equation for vascular access planning
Risk-based thresholds for arteriovenous (AV) access creation has been proposed to aid vascular access planning. We aimed to assess the clinical impact of implementing the kidney failure risk equation (KFRE) for vascular access referral. 16,102 nephrology-referred chronic kidney disease (CKD) patients from the Swedish Renal Registry 2008-2018 were included. The KFRE was calculated repeatedly, and the timing was identified for when the KFRE risk exceeded several pre-defined thresholds and/or the estimated glomerular filtration rate 50% 94.5 (95% Confidence interval [CI] 94.3–94.7), followed by KFRE>40% 90.0 (95% CI 89.7–90.3), while sensitivity was highest for KFRE>30% 79.3 (95% CI 78.2–80.3) and eGFR50%, KFRE>40%, and eGFR40% over two years and KFRE>50% over 12 months when it is important to avoid the harm of possibly unnecessary surgery. In Sweden, 54% of nephrology-referred patients started hemodialysis in a central venous catheter (CVC) of which only 5% had AV access surgery >6 months before initiation. 60% of the CVC patients exceeded KFRE>40% a median of 0.8 years (interquartile range 0.4-1.5) before KRT initiation. The utility of using KFRE>40% and KFRE>50% is higher compared to the more traditionally used eGFR threshold 2 for vascular access planning.
- 14 March 2024
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 39 (12) , 2079-2087
Open AccessClinical impact of the Kidney Failure Risk Equation for vascular access planning
Risk-based thresholds for arteriovenous (AV) access creation has been proposed to aid vascular access planning. We aimed to assess the clinical impact of implementing the kidney failure risk equation (KFRE) for vascular access referral. 16,102 nephrology-referred chronic kidney disease (CKD) patients from the Swedish Renal Registry 2008-2018 were included. The KFRE was calculated repeatedly, and the timing was identified for when the KFRE risk exceeded several pre-defined thresholds and/or the estimated glomerular filtration rate 50% 94.5 (95% Confidence interval [CI] 94.3–94.7), followed by KFRE>40% 90.0 (95% CI 89.7–90.3), while sensitivity was highest for KFRE>30% 79.3 (95% CI 78.2–80.3) and eGFR50%, KFRE>40%, and eGFR40% over two years and KFRE>50% over 12 months when it is important to avoid the harm of possibly unnecessary surgery. In Sweden, 54% of nephrology-referred patients started hemodialysis in a central venous catheter (CVC) of which only 5% had AV access surgery >6 months before initiation. 60% of the CVC patients exceeded KFRE>40% a median of 0.8 years (interquartile range 0.4-1.5) before KRT initiation. The utility of using KFRE>40% and KFRE>50% is higher compared to the more traditionally used eGFR threshold 2 for vascular access planning.